Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.
Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.
Hope for FDA authority over tobacco products dies in Congress.
Patients urge Medicare to allow an open formulary for cancer treatment.
Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.
Funding opportunities listed.
Trending Stories
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- NCI releases names of members of ad hoc working group—filling the void left by BSA
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines - NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium